What is FineHeart?
FineHeart operates at the intersection of advanced engineering and life-saving medical intervention. The company is primarily recognized for the development of the Intra Cardiac Output Management System (ICOMS), a sophisticated intracardiac pump designed to augment native ejection fraction. By providing a less invasive alternative to traditional cardiac assist devices, FineHeart is carving out a significant niche in the global MedTech market. The firm's focus on restoring quality of life for patients with severe heart conditions has attracted a diverse group of institutional backers, ranging from regional private equity firms to specialized cardiovascular impact investors, all aligned with the company's long-term clinical objectives.
How much funding has FineHeart raised?
FineHeart has raised a total of $30.9M across 2 funding rounds:
Series A
$7.2M
Series B
$23.7M
Series A (2016): $7.2M with participation from Galia Gestion, Broadview Ventures, and Sofimac
Series B (2021): $23.7M led by Lauak Group, Verve Ventures, and Doliam's Companies
Key Investors in FineHeart
Lauak Group
Lauak Groupe is a prominent manufacturer of aerospace parts and structures that brings industrial precision and manufacturing expertise to the MedTech sector.
Verve Ventures
Verve Ventures is a network-driven venture capital firm based in Switzerland that specializes in supporting high-growth health and bio-technology startups across Europe.
Doliam's Companies
Doliam is a private investment entity focused on accelerating the growth of high-tech and MedTech solutions through strategic operational guidance.
What's next for FineHeart?
Following this major enterprise-level funding, FineHeart is expected to prioritize the scaling of its clinical trials and the refinement of its manufacturing processes for the ICOMS platform. The strategic backing from both industrial partners and venture capital firms provides the necessary runway to navigate the complex regulatory landscape of medical device commercialization. As the company transitions from development to potential market entry, the focus will likely shift toward establishing strategic partnerships with healthcare providers and expanding its footprint in the international cardiology market. This growth trajectory suggests a pivotal phase for the company as it seeks to validate its technology as a standard-of-care alternative for heart failure management.
See full FineHeart company page
